Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trialShaji Kumar, Philippe Moreau, Rakesh Popat et al.|The Lancet Oncology|2020Cited by 401
Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MMPhilippe Moreau, Simon J. Harrison, Asher Chanan‐Khan et al.|Blood|2017Cited by 271